News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaccinex Inc
(NQ:
VCNX
)
5.200
+0.470 (+9.94%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vaccinex Inc
< Previous
1
2
Next >
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
Today 8:30 EDT
Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s disease
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
July 31, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
July 17, 2024
Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progression
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
June 06, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
April 02, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
February 21, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex, Inc. Announces Reverse Stock Split
February 15, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
February 07, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
December 04, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
October 26, 2023
Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
October 31, 2023
Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with...
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Announces Pricing of $9.6 Million Public Offering
September 28, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
September 28, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
September 26, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex, Inc. Announces Reverse Stock Split
September 22, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
June 01, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
April 25, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
April 12, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Announces Private Placement with Commitments of $5.0 Million
April 03, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
April 03, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 23, 2023
March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
March 21, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
March 09, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
MarketBeat Week in Review – 2/6 - 2/10
February 11, 2023
Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.